Autolus Therapeutics plc Autolus Therapeutics plc

Autolus Therapeutics plc

AUTL

Rank in Stocks #14726
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily... Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
Share Price
$1.09
Last synced: 2026-11-17
Market Cap
$290.16M
Change (1 day)
-4.39%
Change (1 year)
-11.38%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
Operating Margin for Autolus Therapeutics plc (AUTL)
Operating Margin as of November 2026 TTM: -159.57%
According to Autolus Therapeutics plc's latest financial reports, its current operating margin (TTM) is -159.57%. At the end of 2025 the company had an operating margin of -372.45%.
Operating Margin history for Autolus Therapeutics plc from 2015 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) -159.57% -57.16%
2025 -372.45% -84.39%
2024 -2,385.63% -77.46%
2023 -10,583.10% 358.75%
2022 -2,306.96% -75.23%
2021 -9,314.80% -47.30%
2020 -17,675.39% 107.61%
2019 -8,513.76% 54.69%
2018 -5,503.74% 297.89%
2017 -1,383.23% 16.62%
2016 -1,186.14% -86.23%
2015 -8,613.76% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
-195.39% -98.78%
US
33.87% -100.21%
US
-116.04% -99.27%
US
25.57% -100.16%
AU
31.23% -100.20%
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

Questions about Autolus Therapeutics plc's operating margin

What is Autolus Therapeutics plc's operating margin?

Autolus Therapeutics plc's operating margin is -159.57%, as of Nov 2026.

What was Autolus Therapeutics plc's operating margin in 2025?

In 2025, Autolus Therapeutics plc's operating margin was -372.45%, compared with -2,385.63% in 2024.

How has Autolus Therapeutics plc's operating margin changed since 2020?

From 2020 to 2025, Autolus Therapeutics plc's operating margin was highest in 2025 (-372.45%) and lowest in 2020 (-17,675.39%).

How does Autolus Therapeutics plc's operating margin compare with similar companies?

Autolus Therapeutics plc's operating margin (-159.57%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.